HSPB8 and cancer: H11/HspB8 is also silenced by aberrant DNA methylation in prostate cancer and Ewing's sarcoma cells [36] and in hematologic malignancies [39] and its restored expression (e.g., by treatment with the demethylating agent Aza-C) induced cell death in all these cancers and inhibited tumor growth in xenograft models [36–39].